Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208437 | 0.96 | ADORA2A (0.49) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7202526 | 0.94 | ADORA2A (0.41) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7207396 | 0.93 | ADORA2A (0.48) | ADORA2AADORA3ADORA2B | |
| Formic Acid SCHEMBL7208433 | 0.91 | ADORA2A (0.52) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7202523 | 0.91 | ADORA2A (0.43) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7208180 | 0.90 | ADORA2A (0.54) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7207402 | 0.89 | ADORA2A (0.49) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7203861 | 0.89 | ADORA2A (0.63) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7202169 | 0.87 | ADORA2A (0.42) | ADORA2AADORA3ADORA2B | |
| SCHEMBL7569532 | 0.87 | ADORA2A (0.45) | ADORA2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610665-B1 | Treatment of inflammatory diseases, asthma or chronic obstructive pulmonary disease | SMITHKLINE BEECHAM CORPORATION | 2003-08-26 | — | — | US | disclosed |
| EP-1056759-B1 | 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-09-04 | — | — | EP | disclosed |